Affiliations 

  • 1 USM-ALPS Joint Laboratory for Heart Research, Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200, Kepala Batas, Pulau Pinang, Malaysia
  • 2 Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang Henan, 453003, P. R. China
  • 3 USM-ALPS Joint Laboratory for Heart Research, Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200, Kepala Batas, Pulau Pinang, Malaysia. ooijerping@usm.my
  • 4 Henan Key Laboratory of Cardiac Reconstruction and Heart Transplantation, Zhengzhou the Seventh People's Hospital, Zhengzhou, 45300, Henan, P. R. China. gzk@xxmu.edu.cn
PMID: 39164600 DOI: 10.1007/s12265-024-10553-3

Abstract

Intrapericardial administration has been proposed as an alternative delivery route of pharmacological agents via the bilaminar sac of pericardium surrounding the heart. To date, intrapericardial administration has entailed the localized administration of a broad spectrum of therapeutic agents. These agents include stem cells, extracellular matrix, growth factor, drugs, bioactive materials, and genetic materials, to the heart and coronary arteries. The route not only overcomes the limitations associated with traditional systemic administration methods, but also presents multiple intrinsic advantages over the other approaches, allowing greater therapeutic actions. Intrapericardial administration exhibits versatility in addressing certain cardiac conditions and ongoing research in this field certainly holds promise for further innovations and advancements to improve cardiac treatment. Thus, this review discusses the anatomy and physiology of the pericardium, the intrapericardial administration access routes, the recent application of intrapericardial delivery in the context of cardiac repair as well as the challenges associated with the approach.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.